Investment
Features
FeesSafety
Academy
More
Pluang+

Compare LYFT Inc (LYFT) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

LYFT Inc vs Novavax Inc — how do they compare? LYFT Inc trades at $17.55 (market cap $6.53B), while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: LYFT Inc is far larger — about 5× Novavax Inc's market cap. Which is the better fit depends on your goals.

LYFTNVAX
Market Cap
$6.53B$1.30B
Sector
IndustrialsHealth
52-Week High
$24.57$11.19
52-Week Low
$12.65$6.22
Enterprise Value
$6.00B$879.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

LYFT Inc

Lyft trades at $17.46, up 7.12% in the past 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, though recent Q2 2026 earnings missed estimates. Positive cash flow trends and record active riders above 30 million signal operational strength, while an ongoing legal investigation presents a headwind.

The outlook is mixed: valuation ratios like P/E of 2.54 appear attractive, and analyst consensus targets $19.17, but earnings misses and competitive pressures weigh on sentiment. Key risks include fiduciary duty investigations and moderating booking growth, requiring careful monitoring of execution against guidance.

Novavax Inc

Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.

Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About LYFT Inc

Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Read more on LYFT

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX